<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01481129</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-00081</org_study_id>
    <secondary_id>NCI-2012-00081</secondary_id>
    <secondary_id>LEONB-ET-2011-041</secondary_id>
    <secondary_id>2011-001970-25</secondary_id>
    <secondary_id>CDR0000716384</secondary_id>
    <secondary_id>ET-2011-041</secondary_id>
    <secondary_id>9022</secondary_id>
    <nct_id>NCT01481129</nct_id>
  </id_info>
  <brief_title>Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Phase 2 Study of MK-2206 in Patients With Relapsed or Refractory Diffuse Large-B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well Akt inhibitor MK2206 works in treating patients with
      relapsed or refractory diffuse large B-cell lymphoma. Akt inhibitor MK2206 may stop the
      growth of cancer cells by blocking some of the enzymes needed for cell growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the antitumor activity of Akt inhibitor MK2206 (MK2206) in terms of objective
      response rate (ORR) at 4 months (complete response [CR], and partial response [PR]) as per
      the 2007 International Cheson response criteria.

      SECONDARY OBJECTIVES:

      I. To evaluate the antitumor activity of MK2206 in terms of ORR at 4 months (CR, unconfirmed
      complete response [CRu], and PR) as per the 1999 International Cheson response criteria.

      II. To determine the duration of response, defined as the time from the date of the best
      response to the date of progression.

      III. To determine the progression-free survival and overall survival of these patients.

      IV. To determine the safety of MK2206. V. To identify predictive biomarkers for treatment
      outcome. (exploratory) VI. To conduct a pharmacodynamic study using FDG-PET scans.
      (exploratory)

      OUTLINE: This a multicenter study.

      Patients receive Akt inhibitor MK2206 orally (PO) once weekly on days 1, 8, 15, and 22.
      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate According to the International Response Criteria for DLBCL (Cheson 2007)</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Rate of CR + PR according to Cheson 2007 after 4 months of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Described in responding subjects using descriptive statistics (median, extreme values, etc.).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the date of inclusion to the date of death from any cause, assessed up to 4 years</time_frame>
    <description>Analyzed using the Kaplan-Meier method. The median survival rates will be reported with a 95% confidence interval. Median follow-up will be calculated using the reverse Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From the date of inclusion to the date of first documented disease progression, relapse or death from any cause, assessed up to 4 years</time_frame>
    <description>Analyzed using the Kaplan-Meier method. The median survival rates will be reported with a 95% confidence interval. Median follow-up will be calculated using the reverse Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (Akt inhibitor MK2206)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Akt Inhibitor MK2206</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (Akt inhibitor MK2206)</arm_group_label>
    <other_name>MK2206</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (Akt inhibitor MK2206)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (Akt inhibitor MK2206)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diffuse large B-cell lymphoma

               -  Relapsed or refractory disease

          -  Measurable disease

               -  At least one measurable lymph node mass that is &gt; 1.5 cm in two perpendicular
                  dimensions and that has not been previously irradiated or has grown since
                  previous irradiation

                    -  Dominant lymph node masses include up to 6 nodal masses that are clearly
                       measurable in 2 perpendicular dimensions and &gt; 1.5 cm in each dimension

                    -  Measurement may be by radiographic imaging

                    -  If there are lymph node masses in the mediastinum or pelvis larger than 1.5
                       cm in 2 perpendicular dimensions, they should always be chosen as dominant
                       masses

                    -  The dominant masses should be from as disparate regions of the body as
                       possible

               -  Measurable sites of disease are also extra-nodal sites such as splenic nodules
                  and hepatic nodules that are thought to contain lymphoma, and are greater than 1
                  cm in the longest transverse dimension

          -  Must have received at least two prior treatment lines; there is no maximal limit on
             the number of prior therapies

               -  Prior treatment must include CHOP (cyclophosphamide, doxorubicin, vincristine,
                  and prednisolone)-like chemotherapy in combination with rituximab

                    -  Rituximab used alone is not considered as a separate regimen

                    -  Salvage treatment, mobilization chemotherapy, high-dose chemotherapy, and
                       planned post-transplant therapy should be considered as one regimen

               -  Relapsed or refractory patients who are candidates for high-dose chemotherapy and
                  autologous or allogeneic stem cell transplantation are not eligible

          -  Tumor tissue sample must be available for pathological review

          -  No known CNS involvement

          -  ECOG performance status &lt; 2 (Karnofsky &gt; 60%)

          -  Life expectancy &gt; 4 months

          -  Absolute neutrophil count &gt;= 1,500/µL

          -  Platelets &gt;= 100,000/µL (&gt;= 75,000/µL if the bone marrow is involved)

          -  Total bilirubin =&lt; 1.5 X institutional upper limit of normal (ULN)

          -  AST(SGOT)/ALT(SGPT) =&lt; 2.5 X ULN

          -  Calculated creatinine clearance &gt;= 50 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Women of child-bearing potential and men must agree to use adequate contraception

          -  Must be able to swallow whole tablets

               -  Nasogastric or G-tube administration is not allowed

               -  Tablets must not be crushed or chewed

          -  Patients with French Social Security in compliance with the French law relating to
             biomedical research allowed

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to MK2206 tablets

          -  Hyperglycemia should be well controlled on oral agents

          -  Cardiovascular baseline QTcF =&lt; 450 msec (male) or QTcF =&lt; 470 msec (female)

          -  No uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  No HIV-positive patients on combination antiretroviral therapy

          -  No patients with malabsorption syndrome or other condition that would interfere with
             intestinal absorption

          -  No patients with clinically important history of liver disease, including viral or
             other hepatitis or cirrhosis

          -  No prior history of malignancies other than lymphoma (except for basal cell or
             squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast)
             unless the subject has been free of the disease for &gt;= 3 years

          -  Must have recovered from adverse events due to agents administered more than 4 weeks
             earlier

          -  Patients must have discontinued all prior therapies for at least 5 times the half-life
             of all prior anticancer therapies before study entry

          -  Prior treatment could include high-dose chemotherapy with autologous stem-cell
             transplantation if patients had progressed &gt;= 3 months after this treatment

          -  No chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin
             C)

          -  Patients must not be receiving any other investigational agents

          -  No other investigational or commercial agents or therapies may be administered with
             the intent to treat the patient's malignancy

          -  No concurrent radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herve Ghesquieres</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopitaux de Paris</name>
      <address>
        <city>Vellefaux</city>
        <state>Paris</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie Cancer Center</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henri Mondor University-Hospital Center</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Claude Huriez Chru</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2011</study_first_submitted>
  <study_first_submitted_qc>November 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2011</study_first_posted>
  <results_first_submitted>December 2, 2016</results_first_submitted>
  <results_first_submitted_qc>February 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 7, 2017</results_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Akt Inhibitor MK2206)</title>
          <description>Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Akt Inhibitor MK2206: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Akt Inhibitor MK2206)</title>
          <description>Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Akt Inhibitor MK2206: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.9" lower_limit="43.7" upper_limit="85.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate According to the International Response Criteria for DLBCL (Cheson 2007)</title>
        <description>Rate of CR + PR according to Cheson 2007 after 4 months of treatment</description>
        <time_frame>Up to 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Akt Inhibitor MK2206)</title>
            <description>Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Akt Inhibitor MK2206: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate According to the International Response Criteria for DLBCL (Cheson 2007)</title>
          <description>Rate of CR + PR according to Cheson 2007 after 4 months of treatment</description>
          <units>objective response</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Described in responding subjects using descriptive statistics (median, extreme values, etc.).</description>
        <time_frame>up to 4 years</time_frame>
        <population>No responses were observed</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Akt Inhibitor MK2206)</title>
            <description>Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Akt Inhibitor MK2206: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Described in responding subjects using descriptive statistics (median, extreme values, etc.).</description>
          <population>No responses were observed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Analyzed using the Kaplan-Meier method. The median survival rates will be reported with a 95% confidence interval. Median follow-up will be calculated using the reverse Kaplan-Meier method.</description>
        <time_frame>From the date of inclusion to the date of death from any cause, assessed up to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Akt Inhibitor MK2206)</title>
            <description>Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Akt Inhibitor MK2206: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Analyzed using the Kaplan-Meier method. The median survival rates will be reported with a 95% confidence interval. Median follow-up will be calculated using the reverse Kaplan-Meier method.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="2.8" upper_limit="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Analyzed using the Kaplan-Meier method. The median survival rates will be reported with a 95% confidence interval. Median follow-up will be calculated using the reverse Kaplan-Meier method.</description>
        <time_frame>From the date of inclusion to the date of first documented disease progression, relapse or death from any cause, assessed up to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Akt Inhibitor MK2206)</title>
            <description>Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Akt Inhibitor MK2206: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Analyzed using the Kaplan-Meier method. The median survival rates will be reported with a 95% confidence interval. Median follow-up will be calculated using the reverse Kaplan-Meier method.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" lower_limit="0.8" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0</title>
        <time_frame>Up to 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Akt Inhibitor MK2206)</title>
            <description>Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Akt Inhibitor MK2206: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Akt Inhibitor MK2206)</title>
          <description>Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Akt Inhibitor MK2206: Given PO
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hemolytic uremic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastro intestinal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug overdose accidental</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Distress respiratory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>uremic hemolytic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>arythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>heart palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>digestive bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>lower limbs oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>increase bilrubin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>creatinine clearance decrease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>creatinine increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>eosinophil increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>GGT increase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>QT prolongation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>leucopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>neutrophil decrease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>alkaline phosphatase increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>thrombopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>SGOT increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>albumine decrease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>calcium decrease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>glycaemia increase</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>appetite loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>decreases phosphorus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dysgueusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>mouth ulcers</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>cutaneous eruption</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>cutaneous erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>papule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>prurigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>prurit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>cutaneous rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>maculopapular rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>toxidermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Hervé Ghesquieres</name_or_title>
      <organization>Centre Léon Bérard (now CHLS)</organization>
      <phone>0426556824</phone>
      <email>herve.ghesquieres@chu-lyon.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

